Pyrimidine derivative, method for preparing same and use thereof in medicine
The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
1. A compound represented by formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof:
wherein:
each of R 1 is independently selected from alkyl, halogen, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 7 R 8 , —C(O)NR 7 R 8 , —C(O)R 9 , —C(O)OR 9 or —NR 7 C(O)R 8 , wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 7 R 8 , —C(O)NR 7 R 8 , —C(O)R 9 , —C(O)OR 9 and —NR 7 C(O)R 8 ;
R 2 is selected from:
—NR 4 C(O)CR 5 ═CHR 6 or —NR 4 C(O)C≡CR 5 ;
R 3 is a spiroheterocyclyl, wherein the spiroheterocyclyl is optionally further substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloalkoxy, —NR 7 R 8 , —C(O)NR 7 R 8 , —C(O)R 9 , —C(O)OR 9 and —NR 7 C(O)R 8 ;
each of R 4 is independently selected from hydrogen or alkyl, wherein the alkyl is optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloalkoxy, —NR 7 R 8 , —C(O)NR 7 R 8 , —C(O)R 9 , —C(O)OR 9 and —NR 7 C(O)R 8 ;
R 5 and R 6 are each independently selected from hydrogen, alkyl or halogen, wherein the alkyl is optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloalkoxy, —NR 7 R 8 , —C(O)NR 7 R 8 , —C(O)R 9 , —C(O)OR 9 and —NR 7 C(O)R 8 ;
R 7 , R 8 and R 9 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)R 12 , —C(O)OR 12 and —NR 10 C(O)R 11 ;
alternatively, R 7 and R 8 together with the N atom to which they are attached form a 4 to 8 membered heterocyclyl, wherein the 4 to 8 membered heterocyclic ring contains one or more N, O, S(O) n atoms, and the 4 to 8 membered heterocyclic ring is further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, ═O, —NR 10 R 11 , —C(O)NR 11 R 11 , —C(O)R 12 , —C(O)OR 12 and —NR 10 C(O)R 11 ;
R 10 , R 11 and R 12 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylate;
m is 1, 2, 3 or 4; and
n is 0, 1, or 2.
2. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , which is a compound of formula (II) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof:
3. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from halogen or alkoxy.
4. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is —NHC(O)CH═CH 2 .
5. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is a monospiroheterocyclyl, wherein the monospiroheterocyclyl is optionally further substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl.
6. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 3 is selected from 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered-/5-membered or 5-membered/6-membered monospiroheterocyclyl, wherein the monospiroheterocyclyl is optionally further substituted by alkyl.
7. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 4 , wherein R 3 is selected from:
or
each R 13 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl.
8. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from:
9. A pharmaceutical composition comprising an effective amount of the compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier, excipient or a combination thereof.
10. A method for inhibiting FGFR4, which comprises contacting the receptor with the compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 .
11. A method for inhibiting FGFR4, which comprises contacting the receptor with the pharmaceutical composition according to claim 9 .
12. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 3 , wherein R 1 is selected from chlorine or methoxyl.
13. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 5 , wherein R 3 is selected from 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclyl.
14. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 6 , wherein the alkyl is methyl or ethyl.
15. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 7 , wherein each R 13 is independently selected from hydrogen or alkyl.
16. The compound or the stereoisomer, tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 15 , wherein the alkyl is ethyl.